You will receive alerts when there are new announcements on Motif Bio PLC
Only registered members can use this feature.
Motif Bio is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA.
Motif is confident there is a path to market for iclaprim, it will require a company with deeper pockets to take the putative treatment further.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.